阿西莫司联合小剂量考来烯胺治疗II型高脂血症。
Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.
作者信息
Series J J, Gaw A, Kilday C, Bedford D K, Lorimer A R, Packard C J, Shepherd J
机构信息
Institute of Clinical Biochemistry, Royal Infirmary, Glasgow, Scotland.
出版信息
Br J Clin Pharmacol. 1990 Jul;30(1):49-54. doi: 10.1111/j.1365-2125.1990.tb03742.x.
Abstract
- This study was designed to examine the effects of acipimox 250 mg three times daily and cholestyramine 4 g three times daily on plasma lipids and lipoproteins in 28 hypercholesterolaemic individuals in a prospective double-blind placebo controlled parallel group fashion. 2. Combined treatment with the two agents produced a mean reduction of 27% in plasma total cholesterol and a 32% fall in LDL cholesterol. Plasma triglyceride was reduced by 13% due to a 38% decrement in VLDL cholesterol. 3. In comparison treatment with cholestyramine alone resulted in a 12% fall in plasma cholesterol and a 15% fall in LDL cholesterol. In this group triglycerides and VLDL showed no significant change. 4. Studies of HDL subfraction mass showed that the addition of acipimox to resin therapy produced a mean increment of 45% in HDL2. 5. These results demonstrate the effectiveness of such a well tolerated low dosage combination therapy.
摘要
- 本研究旨在以前瞻性双盲安慰剂对照平行组方式，检验每日三次服用250毫克阿西莫司和每日三次服用4克考来烯胺对28名高胆固醇血症患者血浆脂质和脂蛋白的影响。2. 两种药物联合治疗使血浆总胆固醇平均降低27%，低密度脂蛋白胆固醇降低32%。由于极低密度脂蛋白胆固醇降低38%，血浆甘油三酯降低了13%。3. 相比之下，单独使用考来烯胺治疗使血浆胆固醇降低12%，低密度脂蛋白胆固醇降低15%。该组中甘油三酯和极低密度脂蛋白无显著变化。4. 高密度脂蛋白亚组分质量研究表明，在树脂疗法中添加阿西莫司使高密度脂蛋白2平均增加45%。5. 这些结果证明了这种耐受性良好的低剂量联合疗法的有效性。
相似文献
1
Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.阿西莫司联合小剂量考来烯胺治疗II型高脂血症。
Br J Clin Pharmacol. 1990 Jul;30(1):49-54. doi: 10.1111/j.1365-2125.1990.tb03742.x.
2
A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia.消胆胺与普罗布考治疗家族性高胆固醇血症的比较。
Atherosclerosis. 1984 Oct;53(1):1-7. doi: 10.1016/0021-9150(84)90099-6.
3
Decrease in LDL and increase in HDL concentrations in type II hyperlipoproteinaemic patients on low-dose combination therapy of cholestyramine and Complamin.
Atherosclerosis. 1988 Feb;69(2-3):97-101. doi: 10.1016/0021-9150(88)90001-9.
4
A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.阿西莫司对非肥胖2型糖尿病患者血脂、血糖控制及胰岛素作用影响的双盲研究。
Diabet Med. 1992 Dec;9(10):908-14. doi: 10.1111/j.1464-5491.1992.tb01730.x.
5
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.非诺贝特和依折麦布单药治疗及联合用药对混合型高脂血症患者脂蛋白亚组分内胆固醇质量和低密度脂蛋白峰值粒径的影响。
Metabolism. 2008 Jun;57(6):796-801. doi: 10.1016/j.metabol.2008.01.026.
6
Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia.
QJM. 1997 Oct;90(10):631-4. doi: 10.1093/qjmed/90.10.631.
7
Effects of combination cholestyramine-neomycin treatment on plasma lipoprotein concentrations in type II hyperlipoproteinemia.消胆胺-新霉素联合治疗对II型高脂蛋白血症患者血浆脂蛋白浓度的影响。
Am J Cardiol. 1985 May 1;55(11):1282-6. doi: 10.1016/0002-9149(85)90489-8.
8
On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia.关于膳食n-3脂肪酸（Maxepa）对高脂血症患者血浆脂质和脂蛋白的影响
Atherosclerosis. 1985 Jan;54(1):75-88. doi: 10.1016/0021-9150(85)90155-8.
9
10
Effects of acipimox and cholestyramine on serum lipoproteins, non-cholesterol sterols and cholesterol absorption and elimination.阿西莫司和考来烯胺对血清脂蛋白、非胆固醇固醇以及胆固醇吸收与清除的影响。
Eur J Clin Pharmacol. 1989;37(2):111-5. doi: 10.1007/BF00558216.
本文引用的文献
1
Combined drug therapy for familial hypercholesterolemia.
Artery. 1980;7(4):281-9.
2
Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen.采用联合用药方案使杂合子家族性高胆固醇血症患者的低密度脂蛋白水平正常化。
N Engl J Med. 1981 Jan 29;304(5):251-8. doi: 10.1056/NEJM198101293040502.
3
Ultracentrifugal subfractionation of high-density lipoprotein.
Analyst. 1984 Mar;109(3):347-51. doi: 10.1039/an9840900347.
4
Influence of bile acids on the soluble phosphatidic acid phosphates in rat liver.
Biochem Biophys Res Commun. 1981 May 29;100(2):606-12. doi: 10.1016/s0006-291x(81)80219-7.
5
Effect of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia during the first week of treatment.烟酸对高脂蛋白血症患者治疗第一周血浆脂质的影响。
J Atheroscler Res. 1968 Jul-Aug;8(4):667-77. doi: 10.1016/s0368-1319(68)80025-0.
6
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.血清胆固醇、脂蛋白与冠心病风险。弗雷明汉姆研究。
Ann Intern Med. 1971 Jan;74(1):1-12. doi: 10.7326/0003-4819-74-1-1.
7
Stimulatory effect of dietary lipid and cholestyramine on hepatic HMG CoA reductase.
J Lipid Res. 1972 Nov;13(6):797-801.
8
Lack of pharmacokinetic interaction between cholestyramine and acipimox, a new lipid lowering drug.考来烯胺与一种新型降脂药物阿昔莫司之间不存在药代动力学相互作用。
Br J Clin Pharmacol. 1986 Oct;22(4):496-7. doi: 10.1111/j.1365-2125.1986.tb02926.x.
9
10
Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial.
Atherosclerosis. 1988 Mar;70(1-2):115-21. doi: 10.1016/0021-9150(88)90105-0.
Zotero 插件